• Journal of Korean Ophthalmic Optics Society
• /
• v.21 no.2
• /
• pp.137-146
• /
• 2016

Purpose: The relationship between retinal conditions such as macular thickness and retinal volume of the eyes with central serous chorioretinopathy(CSC) and visual acuity was investigated. Methods: A total of 136 eyes from 78 subjects was divided into 5 groups: CSC eyes under treatment and its asymptomatic contralateral eyes, fully cured CSC eyes after the diagnosis and its contralateral, and normal eyes. Their uncorrected visual acuity(UCVA), best corrected visual acuity(BCVA), retinal thickness and retinal volume were further examined. Results: All of UCVA, BCVA, retinal thickness and retinal volume of CSC eyes under treatment were significantly different from those of asymptomatic contralateral eyes, fully cured CSC eyes and normal eyes. BCVA of the asymptomatic contralateral eyes was not significantly different from it of normal eyes, however, its retinal thickness and volume were significantly different from those of normal eyes. Increased degree of retinal volume along with the increase of retinal volume was greater in CSC eyes and its asymptomatic contralateral eyes, fully cured CSC eyes and its contralateral eyes than normal eyes. Conclusions: From the present study, it was revealed that the retinal thickness and volume of asymptomatic contralateral eyes of CSC increase as well as CSC eyes, and the change of BCVA due to CSC occurs only when the retinal thickness and volume increase in some extent.

• Journal of The Korean Ophthalmological Society
• /
• v.59 no.12
• /
• pp.1152-1159
• /
• 2018

Purpose: We prospectively investigated clinical changes and long-term outcomes after administration of the drugs recommended by the Age-Related Eye Disease Study-2 to patients with intermediate age-related macular degeneration (AMD). Methods: This prospective multicenter study enrolled 79 eyes of 55 patients taking lutein and zeaxanthin. The primary endpoint was contrast sensitivity; this was checked every 12 months for a total of 36 months after treatment commenced. The secondary endpoints were visual acuity, central macular thickness, and drusen volume; the latter two parameters were assessed using spectral domain optical coherence tomography. Results: The mean patient age was $72.46{\pm}7.16years$. Contrast sensitivity gradually improved at both three and six cycles per degree. The corrected visual acuity was $0.13{\pm}0.14logMAR$ and did not change significantly over the 36 months. Neither the central macular thickness nor drusen volume changed significantly. Conclusions: Contrast sensitivity markedly improved after treatment, improving vision and patient satisfaction. Visual acuity, central retinal thickness, and drusen volume did not deteriorate. Therefore, progression of AMD and visual function deterioration were halted.